Stockscreener 앱 받기
12.41
1.80%
0.22
시간 외 거래:
12.01
-0.40
-3.22%
전일 마감가:
$12.19
열려 있는:
$12.48
하루 거래량:
1.39M
Relative Volume:
1.17
시가총액:
$1.04B
수익:
$7.62M
순이익/손실:
$-271.60M
주가수익비율:
-3.5439
EPS:
-3.5018
순현금흐름:
$-271.54M
1주 성능:
-1.97%
1개월 성능:
-9.15%
6개월 성능:
-21.51%
1년 성능:
+18.42%
1일 변동 폭
$12.17
$13.03
1주일 범위
$12.06
$13.23
52주 변동 폭
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.41 | 1.02B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc - TradingKey
EyePoint, Inc. Revenue Breakdown – NASDAQ:EYPT - TradingView
EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
J.P. Morgan Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan
EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan
Form 144 EyePoint For: 21 July By Investing.com - Investing.com South Africa
EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan
Price to earnings forward of EyePoint, Inc. – MUN:PV3B - TradingView
Drug company to pay $4.7M after admitting it paid providers to use its product - Yahoo Finance
Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations - watertownmanews.com
EyePoint to pay $4.6M to settle with DOJ over kickback claims - MSN
EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald
EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations - Moomoo
EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations - Moomoo
Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHASEC Filing - TradingView
EyePoint Pharmaceuticals (EYPT) Settles for $4.6M Over Kickback Allegations - GuruFocus
EyePoint (NASDAQ: EYPT) signs five-year federal Corporate Integrity Agreement - Stock Titan
United States: EyePoint Pharmaceuticals To Pay $4.6 Million To Resolve False Claims Act Allegations - The St Kitts Nevis Observer
EyePoint Agrees To Pay $4.65M To U.S. Government In FCA Suit Settlement - Mealey's
EyePoint to pay $4.6M to settle with DoJ over kickback claims - Seeking Alpha
Stifel Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
EYPT Initiated Coverage by Stifel -- Buy Rating with $40 Price T - GuruFocus
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Two New EyePoint Employees Receive Options for 63,500 Shares - Stock Titan
Stifel initiates EyePoint stock with buy rating on retinal drug potential By Investing.com - Investing.com South Africa
Stifel initiates EyePoint stock with buy rating on retinal drug potential - Investing.com Nigeria
Stifel Initiates EyePoint(EYPT.US) With Buy Rating, Announces Target Price $40 - Moomoo
EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes - Stock Titan
Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer - VisionMonday.com
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
EyePoint Appoints Retina Specialist Tarek S. Hassan as Chief Strategic Science Officer - citybiz
EyePoint Appoints Retina Specialist Dr. Tarek S. Hassan as Chief Strategic Science Officer - Quiver Quantitative
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer - marketscreener.com
Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st
ETFs Investing in EyePoint, Inc. Stocks - TradingView
EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - AD HOC NEWS
EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):